The estimated Net Worth of Corp /De/Celgene Switzerlan... is at least $60.9 Million dollars as of 23 January 2017. Corp Switzerlan owns over 851,154 units of Agios Pharmaceuticals Inc stock worth over $60,908,482 and over the last 8 years Corp sold AGIO stock worth over $0.
Corp has made over 1 trades of the Agios Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Corp bought 851,154 units of AGIO stock worth $57,027,318 on 23 January 2017.
The largest trade Corp's ever made was buying 851,154 units of Agios Pharmaceuticals Inc stock on 23 January 2017 worth over $57,027,318. On average, Corp trades about 851,154 units every 0 days since 2017. As of 23 January 2017 Corp still owns at least 1,374,599 units of Agios Pharmaceuticals Inc stock.
You can see the complete history of Corp Switzerlan stock trades at the bottom of the page.
Over the last 11 years, insiders at Agios Pharmaceuticals Inc have traded over $77,887,085 worth of Agios Pharmaceuticals Inc stock and bought 3,229,562 units worth $154,554,190 . The most active insiders traders include Kevin P Starr, Robert Nelsen und John Maraganore. On average, Agios Pharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $765,588. The most recent stock trade was executed by Rahul D. Ballal on 11 August 2024, trading 2,302 units of AGIO stock currently worth $102,002.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Agios Pharmaceuticals Inc executives and other stock owners filed with the SEC include: